About ProImmune

Contact Us

ProImmune News


ProImmune Publications

ProImmune Newsletters

Mastering Immunity

ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and  integrated antigen characterization platform, and products and services for tracking antigen-specific immune responses with state-of-the-art ELISpot and flow cytometry techniques. We are committed to helping you take your studies to success through product innovation, responsive service and focused application support, saving you time and money and reducing risk.


The Story of ProImmune...

The study of immunology isn’t only relevant to illness. Every foreign agent that enters the body has the potential to provoke a response from the immune system. Usually, this keeps us disease-free, as ‘self’ is tolerated and ‘non-self’ attacked and eliminated. When ‘self’ is mistakenly attacked, we see the development of autoimmune disease, and when ‘non-self’ gets the upper hand we fall prey to acute or chronic infections. Researchers developing vaccines seek to enhance the immune response to pathogens to prime the body’s own arsenal against future infections. On the flip side, every drug and even every food, cosmetic or other household additive can potentially generate unwanted immune responses and nobody wants to be allergic to their shampoo or breakfast cereal.

Everyone from medical researchers to household brands needs to know exactly which substances can stimulate the immune system, and which substances can sneak under the radar. Portions of substances that the immune system can recognise are called epitopes, and identifying potential epitopes and monitoring the immune response to them is where ProImmune has become a world leader.

Dr. Linda Tan & Dr. Nikolai Schwabe

Dr. Linda Tan & Dr. Nikolai Schwabe

Dr Linda Tan and Dr Nikolai Schwabe founded ProImmune in 2000. The business has never relied on outside investment, and this independence from external investors continues to allow ProImmune to pursue its own business direction.

Building on Linda’s PhD work at Oxford's Weatherall Institute of Molecular Medicine, among ProImmune’s early products were Pro5® MHC Pentamers, which are used to detect epitope-specific immune cells so that they can be analyzed in human blood samples.  Pentamers as well as ProT2® MHC Class II Tetramers introduced in 2016 continue to be part of ProImmune’s core business and have gone from strength to strength with more than 1200 peer reviewed publications citing the use of these products.

ProImmune has pro-actively maintained links with its academic roots and contributed to diverse collaborative projects over the years. The company’s motto ‘Mastering Immunity’ reflects the importance to medical science of understanding how the immune system functions. Infectious diseases (eg HIV, Hepatitis, Influenza), cancer, allergies, debilitating autoimmune diseases (eg Rheumatoid Arthritis), and neurodegenerative diseases (eg Multiple Sclerosis), could in principle all be prevented and cured by a correctly functioning immune system. Understanding immunity and how to manage it is key to preventing and curing these diseases and presents an enormous opportunity to address global, unmet medical needs.

To that end, ProImmune offers clients the opportunity to save time by outsourcing aspects of their research programmes or clinical trials. Over the years the company has developed a unique expertise in tracking immune responses and custom epitope-discovery services, which are vital to groups involved in clinical studies on the immune system.

The company is a recognized leader in providing services to for evaluating and managing drug immunogenicity risk at a pre-clinical stage. Nik Schwabe says: “We try to mimic and predict the function of the immune system in laboratory tests that in many cases rely on donated human samples, such as blood and serum, in a way that can also reduce the need for animal testing.”

ProImmune sells its products and services directly to most countries of the world, with exports accounting for the lion share of its business. Linda and Nik have created a highly-skilled team of scientists with a strong focus on research and development, ensuring that the company continues to offer innovative products and services that address the needs of medical researchers. As a result the company now counts most of the world's leading pharmaceutical and biotechnology companies, as well as several thousand academic groups, among its regular customers.


Company Directors

Dr Nikolai Schwabe
Founder, Chief Executive Officer

Nik's responsibility is the day-to-day management of the company's business. Prior to founding ProImmune, Nik was responsible for Business Development and Intellectual Property at Bookham Technology plc, a fibre-optic components maker based in Abingdon, Oxon. Before joining Bookham he worked as a financial analyst at Salomon Brothers International in London, advising clients on financial portfolio strategies. Nik holds a D.Phil. in Theoretical Physics from Oxford University.

Dr Linda Tan
Founder, President & Chief Operating Officer

Linda's responsibility is the day-to-day management of ProImmune's operations. Before founding ProImmune, Linda worked at the Institute of Molecular Medicine at Oxford in the laboratory of Prof. Andrew McMichael where her work focused on T cell immunology and the MHC pathway. Linda holds a D.Phil. in Molecular Immunology and a B.A. in Biochemistry, both from Oxford University.